Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

Mizuho Securities analyst Sean Kennedy maintained a Hold rating on Cognizant (CTSH – Research Report) today and set a price target of $87.00.

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $216 from $212 and keeps an Outperform rating ...